American Journal of Nephrology
Original Report: Laboratory Investigation
Effect of Sulodexide on Albuminuria, NAG Excretion and Glomerular Filtration Response to Dopamine in Diabetic PatientsSulikowska B.a · Olejniczak H.c · Muszyńska M.c · Odrowaz-Sypniewska G.b · Gaddi A.d · Savini C.e · Cicero A.F.G.d · Laghi L.d · Manitius J.aaDepartment of Nephrology, Hypertension and Internal Medicine and bClinical Laboratory Department, Nicolaus Copernicus University in Toruń, Collegium Medicum Bydgoszcz, and cDiabetology and Edocrinology Centre, Bydgoszcz, Poland; d‘GC. Descovich’ Atherosclerosis Research Centre, ‘D Campanacci’ Clinical Medicine and Applied Biotechnology Department, Bologna University, Bologna, and eEuropean Commission, DG-Joint Research Centre, IHCP, Biotechnology and GMOs Unit, Ispra, Italy
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: April 10, 2006
Accepted: November 27, 2006
Published online: January 19, 2007
Issue release date: January 2007
Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3
ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)
For additional information: https://www.karger.com/AJN
Abstract
Background: Albuminuria is the best and most readily available marker for glomerular damage and progressive renal function loss in patients with diabetic nephropathy. Recently, administration of the oral glycosaminoglycan sulodexide (a mixture of 80% fast-moving heparin and 20% dermatan sulphate) was shown to effectively decrease albumin excretion rate in diabetics with nephropathy. Aims: To evaluate whether the hypoalbuminuric effect of sulodexide is associated with improvement of the renal vascular or tubule function. Methods: Forty-five type 1 diabetic patients, affected by diabetic nephropathy with albuminuria for at least 5 years, were randomly allocated to sulodexide or untreated. Those allocated to sulodexide were given 100 mg of sulodexide daily for 120 days. Renal vascular function (DIR) and N-acetyl-β-D-glucosaminidase (NAG) excretion were estimated before and at the end of the study, the former in thesulodexide group only. DIR was measured as two Crcl lasting 120 min (before and during 2 µg/kg b.w. i.v. dopamine). Results: The analysis of trends during the study demonstrated a marked reduction of albuminuria in the sulodexide group (from 126.1 ± 15.41 to 93.6 ± 13.7 mg/day). DIR rose from 13.2 ± 2.1% to 15.44 ± 1.9% (relative increase: +16.9%), and NAG excretion showed a decreasing trend decreased in the sulodexide group only (from 5.1 ± 0.62 to 4.7 ± 0.40 U/gcreat). Conclusion: The findings presented in this study indicate for the first time that orally available sulodexide may favorably affect the renal vascular function in type 1 diabetic patients with nephropathy and microalbuminuria. The effect of sulodexide on NAG is strongly influenced by the baseline NAG values, with a significant NAG reduction in the patients with the highest baseline NAG values.
© 2006 S. Karger AG, Basel
Related Articles:
References
- de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309–2320.
- Mogensen CE: Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987;31:673–689.
- de Zeeuw D, Remuzzi G, Parving H-H, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921–927.
- Franz MJ, Wheeler ML: Nutrition therapy for diabetic nephropathy. Curr Diab Rep 2003;3:412–417.
-
Viberti G: Regression of albuminuria: latest evidence for a new approach. J Hypertens 2003;21(suppl 3):S24–S28.
- Gambaro G, Kinalska I, Oksa A, Pont’uch P, Hertlova M, Oslovsky J, Manitius J, Fedele D, Czekalski S, Perusicova J, Skrha J, Taton J, Grzeszczak W, Crepaldi G: Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002;13:1615–1625.
- Gambaro G, Skrha J, Ceriello A: Glycosaminoglycan therapy for long-term diabetic complications? Diabetologia 1998;41:975–979.
- Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Gabrisa S, Milanesi C, Pesarini A, Borsatti A, Marchi E, Baggio B: Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994;46:797–806.
-
Sorensson J, Bjornson A, Ohlson M, Ballermann BJ, Haraldsson B: Synthesis of sulfated proteoglycans by bovine glomerular endothelial cells in culture. Am J Physiol 2003;284:F373–F380.
- Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51:1157–1165.
- Feldt-Rasmussen B: Microalbuminuria, endothelial dysfunction and cardiovascular risk. Diabetes Metab 2000;26(suppl 4):64–66.
-
Kordonouri O, Kahl A, Jorres A, Hopfenmuller W, Muller C, Danne T: The prevalence of incipient tubular dysfunction, but not of glomerular dysfunction, is increased in patients with diabetes onset in childhood. J Diabetes Compl 1999;13:320–324.
External Resources
- Kordonouri O, Hartmann R, Muller C, Danne T, Weber B: Predictive value of tubular markers for the development of microalbuminuria in adolescents with diabetes. Hormn Res 1998;50(suppl 1):23–27.
- Wiland P, Swierkot J, Szechinski J: N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment. Br J Rheumatol 1997;36:59–63.
- Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M, D’Amico G: Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002;17:1890–1896.
- Ruggeri A, Guizzardi S, Franchi M, Morocutti M, Mastacchi R: Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. II. Organ distribution in rats. Arzneimittelforsch 1985;35:1517–1519.
- Cristofori M, Mastacchi R, Barbanti M, Sarret M: Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. I. Pharmacokinetics in rats. Arzneimittelforsch 1985;35:1513–1516.
- Kristova V, Kriska M, Babal P, Djibril MN, Slamova J, Kurtansky A: Evaluation of endothelium-protective effects of drugs in experimental models of endothelial damage. Physiol Res 2000;49:123–128.
- Sulikowska B, Nieweglowski T, Manitius J, LYsiak-Szydlowska W, Rutkowski B: Effect of 12-month therapy with omega-3 polyunsaturated acids on glomerular filtration response to dopamine in IgA nephropathy. Am J Nephrol 2004;24:474–482.
- Gekle M: Renal proximal tubular albumin reabsorption: daily prevention of albuminuria. News Physiol Sci 1998;13:5–11.
- Lemley KV, Blouch K, Abdullah I, Boothroyd DB, Benneth PH, Myers BD, G. Nelson RG: Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol 2000;11:2095–2105.
- Guizar JM, Kornhauser C, Malacara JM, Amador N, Barrera JA, Esparza R: Renal functional reserve in patients with recently diagnosed type 2 diabetes mellitus with and without microalbuminuria. Nephron 2001;87:223–230.
- Sorrenti G, Grimaldi M, Canova N, Palazzini E, Melchionda N: Glycosaminoglycans as a possible tool for micro- and macroalbuminuria in diabetic patients. A pilot study. J Int Med Res 1997;25:81–86.
- Solini A, Vergnani L, Ricci F, Crepaldi G: Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 1997;20:819–823.
- Dedov I, Shestakova M, Vorontzov A, Palazzini E: A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 1997;12:2295–2300.
- Gambaro G, van der Woude FJ: Glycosaminoglycans: use in treatment of diabetic nephropathy. J Am Soc Nephrol 2000;11:359–368.
- Poplawska A, Szelachowska M, Topolska J, Wysocka-Solowie B, Kinalska I: Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res Clin Pract 1997;38:109–114.
- Crepaldi G, Rossi A, Coscetti G, Abbruzzese E, Calveri U, Calabro A: Sulodexide oral administration influences blood viscosity and fibrinolysis. Drugs Exp Clin Res 1992;18:189–195.
- Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, Forino M, Facchin S, Bordin L, Weigert C, Nerlich A, Schleicher ED: Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 2000;11:2324–2336.
- Gekle M, Knaus P, Nielsen R, Mildenberger S, Freudinger R, Wohlfarth V, Sauvant C, Christensen EI: Transforming growth factor-β1 reduces megalin/cubilin-mediated endocytosis of albumin in proximal tubule derived OK-cells. J Physiol 2003;552:471–481.
- Bosch JP: Renal reserve: a functional view of glomerular filtration rate. Semin Nephrol 1995;15:381–385.
- Zaletel J, Cerne D, Lenart K, Zitta S, Jurgens G, Estelberger W, Kocijancic A: Renal functional reserve in patients wit type 1 diabetes mellitus. Wien Klin Wochenschr 2004;116:246–251.
Article / Publication Details
Received: April 10, 2006
Accepted: November 27, 2006
Published online: January 19, 2007
Issue release date: January 2007
Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3
ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)
For additional information: https://www.karger.com/AJN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
